Beam Therapeutics · 23 hours ago
Senior Director, Value, Evidence & Development Strategy
Cambridge, MA
Full-time
Onsite
Director/Executive
$260K/yr - $320K/yr
10+ years expBeam Therapeutics is a biotechnology company focused on precision genetic medicines. They are seeking a Senior Director to lead the global HEOR strategy for their sickle cell disease program and other emerging pipeline programs, developing evidence-generation plans and managing stakeholder relationships.
BiotechnologyGeneticsMedicalTherapeutics
Responsibilities
Provide strategic input to disease prioritization, target product profiles, clinical trial protocols, clinical development plans, and regulatory submissions; lead development of clinical sections for Investigator’s Brochures, briefing books, safety updates, IND/NDA materials, and responses to Health Authority questions
Develop, validate, and integrate patient‑centered outcomes (PROs) into protocols and analyses
Interpret clinical trial results (including PROs and healthcare resource use) and partner with Clinical Development/Biostatistics on Statistical Analysis Plans (SAPs) and post‑hoc analyses
Lead a fit‑for‑purpose RWE strategy (EHR, claims, registries, hybrid/open datasets) including natural history/registry design and governance to inform endpoints, recruitment, and post‑authorization effectiveness/safety assessments
Develop and operationalize external/synthetic control arm approaches (e.g., matched registry cohorts, Bayesian borrowing) for single‑arm or small‑population studies typical in cell & gene therapy
Provide operational oversight of Medical Affairs evidence generation, including vendor/CRO governance, milestone/deliverable tracking, data‑quality plans, risk management, and on‑time execution across Medical Affairs–led studies; contribute to long‑term capability building (digital health, real‑world studies)
Elicit and integrate perspectives from patients, KOLs, policy leaders, and internal stakeholders (market access, marketing, patient advocacy) to ensure plans meet the needs of patients, HCPs, and payers
Support Market Access on internal and external payer/policy initiatives (pricing and reimbursement, unmet medical need, regional market dynamics, evidence gaps) across the portfolio
Support business decisions around ex-US strategy including, but not limited to, scoping ex-US opportunities, prioritizing country engagement, early scientific advice / parallel consultations with EMA and HTA bodies (e.g., HTACG/JSC), providing advice to development programs on endpoint selection to support product and reimbursement approvals ex-US, etc
Anticipate payer evidence needs and budget‑impact critiques (including preparation for ICER Reviews)
Build and maintain economic models (cost‑effectiveness, budget impact) tailored to one‑time CGTs, addressing uncertainty/durability and caregiver burden
Collaborate with Market Access to design innovative payment models and outcomes‑based agreements with pragmatic outcomes and tracking
Lead the AMCP dossier and pre‑approval information exchange (PIE) strategy (6–12 months pre‑launch)
Work collaboratively with internal teams, consultants, and CROs to advance development of the portfolio
Qualification
Required
Master's Degree or higher in Health Economics and Outcomes Research or a relevant discipline
Formal training in Epidemiology/Health Services Research required
At least 10+ years' experience in observational research study management AND data analytics, either within industry or with an observational research consulting firm
Proven track record in drug development, with rare disease experience and an existing network of hematologists preferred
Demonstrated ability to lead in a matrixed, cross-functional environment, combining strategic agility with strong business acumen
Independent, proactive operator with strong ownership
Cross functional collaboration with Clinical, Regulatory, Commercial, Medical Operations, and Publications while maintaining medical/scientific integrity
Excellent communication, collaboration, and problem-solving skills
Preferred
Proven track record in drug development, with rare disease experience and an existing network of hematologists preferred
Company
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$1.19B2025-03-10Post Ipo Equity· $500M
2021-01-19Post Ipo Equity· $260M
2020-02-11Post Ipo Equity· $207M
Leadership Team
John Evans
CEO
Christine Bellon
Chief Legal Officer
Recent News
2026-01-13
thefly.com
2026-01-13
Company data provided by crunchbase